Matthew Galea is a features writer for CBR. He spends his day as a high school English teacher, and every other minute watching, thinking and writing about movies and television. From Lon Chaney Jr.'s ...

Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

A 10% owner of Werewolf Therapeutics Inc (NASDAQ:HOWL), including MPM Asset Management LLC and related entities, reported selling 160,103 shares of common stock over three days, according to a Form 4 ...

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...

There are tons and tons of scary movies about vampires, demons and ghosts—but werewolf movies tend to only come around once in a blue moon (in other words, far less frequently than the full moons that ...